- In April 2025, Amgen announced a USD 900 million expansion of its biomanufacturing facility in New Albany, Ohio, increasing its total investment in the region to over USD 1.4 billion and creating approximately 750 new jobs. This move underscores Amgen's commitment to bolstering U.S.-based biologics capabilities—especially for monoclonal antibodies and gene therapies—while reinforcing domestic supply chains amid global uncertainties
- In April 2025, Ferring Pharmaceuticals received FDA approval for a second U.S. manufacturing site dedicated to ADSTILADRIN (nadofaragene firadenovec‑vncg) in Parsippany, New Jersey. The facility features sustainable energy integration, marking a significant step in specialized gene therapy production capacity in the Next‑Generation Biomanufacturing space
- In December 2024, China’s Ministry of Industry and Information Technology announced a strategic initiative, directing USD 4.17 billion in investments toward emerging industries—including biomanufacturing—for 2025. This landmark funding drive reinforces China's ambition to become a global leader in future-focused manufacturing technologies
